An innovative two-stage surgical treatment option that leverages the liver’s regenerative capacity is showing promise for some patients with previously unresectable liver metastases from colorectal cancer.
Study reveals that the successful downstaging of advanced HCC via locoregional therapy prior to transplant yields 5-year survival rate of 60 percent. Two liver experts explain the impact on patients and the transplant community.
Cleveland Clinic surgeons used a new transplant protocol to treat a patient with liver metastases from colorectal cancer for the first time in the U.S. Learn how this protocol could improve patient outcomes.
HALT-HCC is practical, easy to implement and outperformed other selection criteria. It has the potential to become a new clinical tool that can lead to more efficient use of donated organs.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Denied surgery elsewhere, a 77-year-old undergoes a complex liver resection for hepatocellular carcinoma with outstanding results.
Cleveland Clinic Liver Tumor Clinic’s Federico Aucejo, MD, discusses how a regional-directed chemotherapy option is providing hope for patients with non-resectable colorectal cancer with liver metastases.
A new treatment option for an aggressive cancer — Cleveland Clinic offers liver transplant for hilar cholangiocarcinoma. Liver replacement offers 70 to 80 percent chance of cure to select patients.
Cleveland Clinic’s Liver Tumor Clinic provides leading-edge, individualized treatment of complex liver cancer in an innovative multidisciplinary model clinic.